ELSEVIER

Atherosclerosis 117 (1995) 311–313

ATHEROSCLEROSIS

# Author index

## Volume 117 (1995)

Abdalla, D.S.P., see Araujo, F.B. **117**, 61
Araujo, F.B., D.S. Barbosa, C.Y. Hsin, R.C. Maranhão, D.S.P. Abdalla, Evaluation of oxidative stress in patients with hyperlipidemia **117**, 61
Aston, C.E., see Kamboh, M.I. **117**, 73

Bagdade, J.D., W.F. Buchanan, T. Pollare, H. Lithell, Abnormal lipoprotein phospholipid composition in patients with essential hypertension **117**, 209
Banning, A.P., see Groves, P.H. **117**, 83
Barbosa, D.S., see Araujo, F.B. **117**, 61
Barger, S.W., see Toborek, M. **117**, 179
Bellomo, G., see Visioli, F. **117**, 25
Bergström, E., O. Hernell, L.A. Persson, B. Vessby, Serum lipid values in adolescents are related to family history, infant feeding, and physical growth **117**, 1
Bijleveld, C., see Joles, J.A. **117**, 51
Bode-Böger, S.M., see Böger, R.H. **117**, 273
Böger, R.H., S.M. Bode-Böger, A. Mügge, S. Kienke, R. Brandes, A. Dwenger, J.C. Frölich, Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production **117**, 273
Brandes, R., see Böger, R.H. **117**, 273
Buchanan, W.F., see Bagdade, J.D. **117**, 209
Bueno, M., see Sarría, A. **117**, 119

Campagnoli, G., see Pazzucconi, F. **117**, 189
Carew, T.E., see Fruebis, J. **117**, 217
Cheadle, H.A., see Groves, P.H. **117**, 83
Chen, B., see Ye, P. **117**, 43

Dahlén, H., see Hong, Y. **117**, 295
Daria Haust, M., Satellite Symposia of the International Symposia on Atherosclerosis — Brief history and selected aspects **117**, 151
Dart, A.M., X. Ling Qi, Determinants of arterial stiffness in Chinese migrants to Australia **117**, 263
de Faire, U., see Hong, Y. **117**, 295
Dinnebier, G., see Menschikowski, M. **117**, 159
Dorigotti, F., see Pazzucconi, F. **117**, 189
Durrington, P.N., see Mackness, M.I. **117**, 145
Dwenger, A., see Böger, R.H. **117**, 273

Evans, R.W., see Kamboh, M.I. **117**, 73

Felgines, C., C. Sérougne, A. Mazur, J. Férézou, C. Lutton, Y. Rayssiguier, Hepatic apolipoprotein and LDL receptor gene expression in the genetically hypercholesterolemic (RICO) rat **117**, 15
Férézou, J., see Felgines, C. **117**, 15
Föger, B., G. Tröbinger, A. Ritsch, M. Lechleitner, T. Hopferwieser, H.-J. Menzel, G. Utermann, K.P. Pfeiffer, J.R. Patsch, Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipo-protein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition **117**, 253
Franceschini, G., see Pazzucconi, F. **117**, 189
Friedlander, Y., see Simons, L.A. **117**, 107
Frölich, J.C., see Böger, R.H. **117**, 273
Fruebis, J., T.E. Carew, W. Palinski, Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits **117**, 217

Gallagher, J.J., N.B. Myant, Erratum to "The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoportein receptor in homozygous familial defective apolipoprotein B-100" [Atherosclerosis 115 (1995) 263] **117**, 309
Galle, J., see Pohl, U. **117**, 169
Galli, C., see Visioli, F. **117**, 25
Garçon, D., see Rahmani-Jourdheuil, D. **117**, 285
Geelen, M.J.H., see Joles, J.A. **117**, 51
Gianfranceschi, G., see Pazzucconi, F. **117**, 189
Giner, A., see Sarría, A. **117**, 119
Groves, P.H., A.P. Banning, W.J. Penny, M.J. Lewis, H.A. Cheadle, A.C. Newby, Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury **117**, 83
Gylling, H., T.A. Miettinen, Rapid communication **117**, 305

Haghpassand, M., J.B. Moberly, 9-*cis*-Retinoic acid increases apolipoprotein AI secretion and mRNA expression in HepG2 cells **117**, 199
Heller, A., see Hong, Y. **117**, 295
Hempel, U., see Menschikowski, M. **117**, 159
Heng, C.K., see Saha, N. **117**, 33
Hennig, B., see Toborek, M. **117**, 179
Hernell, O., see Bergström, E. **117**, 1
Heydari, N., see Pohl, U. **117**, 169
Hong, S., see Saha, N. **117**, 33
Hong, Y., H. Dahlén, N. Pedersen, A. Heller, G.E. McClearn, de Faire, Potential environmental effects on adult lipoprotein(a) levels: results from Swedish twins **117**, 295
Hopferwieser, T., see Föger, B. **117**, 253
Hsin, C.Y., see Araujo, F.B. **117**, 61

Jaross, W., see Menschikowski, M. **117**, 159
Joffe, B.I., see Zouvanis, M. **117**, 147
Joles, J.A., C. Bijleveld, A. van Tol, M.J.H. Geelen, H.A. Koomans, Ovariectomy decreases plasma triglyceride levels in analbuminaemic rats by lowering hepatic triglyceride secretion **117**, 51
Jouni, Z.E., J.J. Winzerling, D.J. McNamara, 1,25-Dihydroxyvitamin $D_3$-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism **117**, 125

Kamboh, M.I., R.W. Evans, C.E. Aston, Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American Black women **117**, 73
Kato, Y., see Seki, J. **117**, 97
Kienke, S., see Böger, R.H. **117**, 273
Koomans, H.A., see Joles, J.A. **117**, 51
Krause, B.R., R.S. Newton, Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models **117**, 237

Larrad, L., see Sarría, A. **117**, 119
Lasierra, M.P., see Sarría, A. **117**, 119
Lattke, P., see Menschikowski, M. **117**, 159
Lázaro, A., see Sarría, A. **117**, 119
Lechleitner, M., see Föger, B. **117**, 253
Lewis, M.J., see Groves, P.H. **117**, 83
Ling Qi, X., see Dart, A.M. **117**, 263
Lithell, H., see Bagdade, J.D. **117**, 209
Low, P.S., see Saha, N. **117**, 33
Lutton, C., see Felgines, C. **117**, 15

Mackness, M.I., P.N. Durrington, Erratum to "Review article: HDL, its enzymes and its potential to influence lipid peroxidation" [Atherosclerosis 115 (1995) 243]☆ **117**, 145
Maguire, S.M., see Tynan, M.B. **117**, 245
Maranhão, R.C., see Araujo, F.B. **117**, 61
Masset, D., see Rahmani-Jourdheuil, D. **117**, 285
Mattson, M.P., see Toborek, M. **117**, 179
Mazur, A., see Felgines, C. **117**, 15
McCallum, J., see Simons, L.A. **117**, 107
McClain, C.J., see Toborek, M. **117**, 179
McClearn, G.E., see Hong, Y. **117**, 295
McMaster, C., see Tynan, M.B. **117**, 245
McNamara, D.J., see Jouni, Z.E. **117**, 125
Menschikowski, M., U. Hempel, G. Dinnebier, P. Lattke, K.-W. Wenzel, W. Jaross, Changes in epitope exposition of apolipoprotein A-I on the surface of high density lipoproteins after phospholipase $A_2$ treatment **117**, 159
Menzel, H.-J., see Föger, B. **117**, 253
Miettinen, T.A., see Gylling, H. **117**, 305
Moberly, J.B., see Haghpassand, M. **117**, 199
Montedoro, G., see Visioli, F. **117**, 25
Moore, R., see Tynan, M.B. **117**, 245
Moreno, L.A., see Sarría, A. **117**, 119
Motoyama, Y., see Seki, J. **117**, 97
Mozoomdar, B.P., see Saha, N. **117**, 33
Mur, M., see Sarría, A. **117**, 119
Mügge, A., see Böger, R.H. **117**, 273
Myant, N.B., see Gallagher, J.J. **117**, 309

Newby, A.C., see Groves, P.H. **117**, 83
Newton, R.S., see Krause, B.R. **117**, 237
Nicholls, D.P., see Tynan, M.B. **117**, 245
Nishio, M., see Seki, J. **117**, 97

Palinski, W., see Fruebis, J. **117**, 217
Patsch, J.R., see Föger, B. **117**, 253
Pazzucconi, F., F. Dorigotti, G. Gianfranceschi, G. Campagnoli, M. Sirtori, G. Franceschini, C.R. Sirtori, Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity **117**, 189
Pearce, J., see Tynan, M.B. **117**, 245
Pedersen, N., see Hong, Y. **117**, 295
Penny, W.J., see Groves, P.H. **117**, 83
Persson, L.A., see Bergström, E. **117**, 1
Pfeiffer, K.P., see Föger, B. **117**, 253
Pohl, U., N. Heydari, J. Galle, Effects of LDL on intracellular free calcium and nitric oxide- dependent cGMP formation in porcine endothelial cells **117**, 169
Pollare, T., see Bagdade, J.D. **117**, 209

Raal, F.J., see Zouvanis, M. **117**, 147
Rahmani, R., see Rahmani-Jourdheuil, D. **117**, 285
Rahmani-Jourdheuil, D., D. Masset, P.-H. Rolland, D. Garçon, R. Rahmani, Abnormal taurocholate ileal transepithelial transport in atherosclerotic mini-pigs and effects of ace inhibitors **117**, 285
Rayssiguier, Y., see Felgines, C. **117**, 15
Reuben, E.M., see Saha, N. **117**, 33
Ritsch, A., see Föger, B. **117**, 253
Roda, L., see Sarría, A. **117**, 119
Rolland, P.-H., see Rahmani-Jourdheuil, D. **117**, 285

Saha, N., C.K. Heng, B.P. Mozoomdar, E.M. Reuben, H.T. Soh, P.S. Low, J.S.H. Tay, Y. Liu, S. Hong, Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease **117**, 33
Sarría, A., L.A. Moreno, M. Mur, A. Lázaro, M.P. Lasierra, L. Roda, A. Giner, L. Larrad, M. Bueno, Lymphocyte T subset counts in children with elevated low-density lipoprotein cholesterol levels **117**, 119
Scheek, L.M., S.A. Wiseman, L.B.M. Tijburg, A. van Tol, Dialysis of isolated low density lipoprotein induces a loss of lipophilic antioxidants and increases the susceptibility to oxidation in vitro **117**, 139
Seftel, H.C., see Zouvanis, M. **117**, 147
Seki, J., M. Nishio, Y. Kato, Y. Motoyama, K. Yoshida, FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty **117**, 97
Sérougne, C., see Felgines, C. **117**, 15
Simons, J., see Simons, L.A. **117**, 107
Simons, L.A., Y. Friedlander, J. McCallum, J. Simons, Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly **117**, 107
Sirtori, C.R., see Pazzucconi, F. **117**, 189
Sirtori, M., see Pazzucconi, F. **117**, 189
Soh, H.T., see Saha, N. **117**, 33
Steele, I.C., see Tynan, M.B. **117**, 245

Tay, Y. Liu, J.S.H., see Saha, N. **117**, 33
Tijburg, L.B.M., see Scheek, L.M. **117**, 139
Toborek, M., S.W. Barger, M.P. Mattson, C.J. McClain, B. Hennig, Role of glutathione redox cycle in TNF-$\alpha$-mediated endothelial cell dysfunction **117**, 179
Trimble, E.R., see Tynan, M.B. **117**, 245
Tröbinger, G., see Föger, B. **117**, 253
Tynan, M.B., D.P. Nicholls, S.M. Maguire, I.C. Steele, C. McMaster, R. Moore, E.R. Trimble, J. Pearce, Erythrocyte membrane fatty acid composition as a marker of dietary compliance in hyperlipidaemic subjects **117**, 245

Utermann, G., see Föger, B. **117**, 253

van Tol, A., see Joles, J.A. **117**, 51
van Tol, A., see Scheek, L.M. **117**, 139
Vessby, B., see Bergström, E. **117**, 1
Visioli, F., G. Bellomo, G. Montedoro, C. Galli, Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents **117**, 25

Wang, S., see Ye, P. **117**, 43
Wendelhag, I., O. Wiklund, J. Wikstrand, Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries **117**, 225
Wenzel, K.-W., see Menschikowski, M. **117**, 159
Wiklund, O., see Wendelhag, I. **117**, 225
Wikstrand, J., see Wendelhag, I. **117**, 225
Winzerling, J.J., see Jouni, Z.E. **117**, 125
Wiseman, S.A., see Scheek, L.M. **117**, 139

Ye, P., B. Chen, S. Wang, Association of polymorphisms of the apolipoprotein B gene with coronary heart disease in Han Chinese **117**, 43
Yoshida, K., see Seki, J. **117**, 97

Zouvanis, M., F.J. Raal, B.I. Joffe, H.C. Seftel, Corrigendum to "Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia: Short communication" [Atherosclerosis 113 (1995) 289] **117**, 147

ELSEVIER

Atherosclerosis 117 (1995) 314–315

ATHEROSCLEROSIS

# Subject index

## Volume 117 (1995)

ACE inhibitors **117**, 285
Acetyl Co-A carboxylase **117**, 51
Activation **117**, 33
AcylCoA:cholesterol acyltransferase (ACAT) **117**, 125
Adolescents **117**, 1
Adrenals **117**, 15
Aging **117**, 295
Alcohol **117**, 295
American Blacks **117**, 73
Analbuminaemia **117**, 51
Angioplasty **117**, 97
Anti-oxidants **117**, 139
Anti-proliferative effect **117**, 97
Antioxidant **117**, 217
Antioxidants **117**, 25
Aortic stiffness **117**, 263
Apo(a) **117**, 73
Apo AI **117**, 199
Apo A-I and cholesterol levels **117**, 73
ApoB **117**, 73, 237
Apo E **117**, 73
Apolipoprotein **117**, 15
Apolipoprotein A-I **117**, 159
Apolipoprotein B **117**, 43
Arterial wall thickness **117**, 225
Asians **117**, 33
Atherosclerosis **117**, 119, 139, 179, 199, 217, 225, 285

B-mode imaging **117**, 225
Blood pressure **117**, 107
Breast feeding **117**, 1
Buthionine sulfoximine **117**, 179

Chinese **117**, 263
Cholesterol **117**, 107, 15
Cholesterol absorption **117**, 305
Cholesterol hypertension **117**, 209
Coronary artery disease **117**, 147
Coronary heart disease **117**, 107, 43
Coronary risk **117**, 33
Cyclic GMP **117**, 97

Diabetes **117**, 107
Dialysis **117**, 139
Diet **117**, 245, 263
Differential risk **117**, 33

EDRF **117**, 169
Elderly **117**, 107
Endothelial barrier function **117**, 179
Endothelium **117**, 273
Environmental **117**, 295
Epitope expression **117**, 159
Erythrocytes **117**, 245

Factor VII **117**, 33
Familial hypercholesterolaemia **117**, 147
Family history **117**, 1
Fatty acid synthase **117**, 51
Fatty acids **117**, 245

Gene **117**, 43

HDL cholesterol **117**, 199
Hepatoma cell **117**, 199
High density lipoproteins **117**, 159
HL-60 cells **117**, 125
HMG-CoA reductase **117**, 237
Hormone **117**, 295
3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase **117**, 125
Hypercholesterolaemia **117**, 273
Hyperlipidaemia **117**, 245
Hypertriglyceridaemia **117**, 51

Incorporation **117**, 285
Intimal thickening **117**, 97
Intracellular calcium **117**, 179
Intracellular free calcium **117**, 169
Inflammatory cytokines **117**, 179

LDL (apo B/E) receptor **117**, 125
LDL cholesterol **117**, 263

LDL receptor **117**, 15
Lipoprotein **117**, 237
Lipoprotein composition **117**, 209
Lipoprotein(a) **117**, 295
Lipoproteins **117**, 33
Liver **117**, 15
Long-term therapy **117**, 189
Low density lipoprotein **117**, 305
Low-density lipoprotein **117**, 139
Low-density lipoprotein cholesterol **117**, 119
Lp(a) **117**, 73

Macrophages **117**, 125
Maternal **117**, 295
Mediterranean diet **117**, 25
Microalbuminuria **117**, 147
Migration **117**, 263
Mini-pigs **117**, 285
Modified low density lipoprotein **117**, 217

*N*-acetyl-L-cysteine **117**, 179
Native LDL **117**, 169
Neointima **117**, 83
Neomycin **117**, 305
Nitric oxide **117**, 169, 273
Nitric oxide donor **117**, 97

Olive oil **117**, 25
Ovariectomy **117**, 51
Oxidation **117**, 139, 217
Oxidative stress **117**, 179
Oxidised LDL **117**, 25, 169

Phospholipid **117**, 209
Phospholipid hydrolysis **117**, 159
Physical growth **117**, 1
Polymerase chain reaction **117**, 43
Polymorphisms **117**, 43, 73
Potassium **117**, 263
Pravastatin **117**, 189
Pulse wave velocity **117**, 263

Restenosis **117**, 83
Retinoid **117**, 199
RICO rat **117**, 15
Risk factors **117**, 107

Scavenger receptor **117**, 125
Serum lipids **117**, 1
Simvastatin **117**, 189
Sitostanol **117**, 305
Smooth muscle cell **117**, 83
Smooth muscle cells **117**, 97
Socio-demographic **117**, 107
Sodium nitroprusside **117**, 169
Superoxide anion **117**, 273

Taurocholate **117**, 285
T lymphocyte subsets **117**, 119
Transcriptional regulation **117**, 199
Transport **117**, 285
Triglycerides **117**, 107, 33
Triton WR-1339, oestradiol **117**, 51
Twins **117**, 295

Ussing chambers **117**, 285

Vitamin A **117**, 199

L-arginine **117**, 169, 273